AU:ATX Stock Latest News
Company AnnouncementsAmplia advances narmafotinib program as pancreatic cancer trial nears completion5d ago
Company AnnouncementsAmplia Therapeutics Secures A$4.78m R&D Tax Rebate to Advance Pancreatic Cancer Trials1w ago
Company AnnouncementsAmplia Therapeutics Advances Narmafotinib Clinical Pipeline in Pancreatic and Ovarian Cancer1w ago
Company AnnouncementsAmplia Showcases FAK Inhibitor Progress at CG Drug and Device Conference2w ago
Company AnnouncementsAmplia Showcases FAK Oncology Pipeline at E&P Healthcare Conference1M ago
Company AnnouncementsAmplia Wins Strong Shareholder Backing for AGM Resolutions and Capital Flexibility2M agoCompany AnnouncementsAmplia Therapeutics Highlights Strong Pancreatic Cancer Data in AGM CEO Presentation2M ago
Company AnnouncementsAmplia Showcases Lead FAK Inhibitor as Pancreatic Cancer Data Strengthen Oncology Push2M ago
- Company AnnouncementsAmplia bolsters narmafotinib case with comprehensive pancreatic cancer data3M ago
Company AnnouncementsAmplia advances FAK inhibitor program with new trials, patent gains and board refresh3M ago
Company AnnouncementsAmplia Therapeutics Issues New Employee Incentive Options3M ago- Company AnnouncementsAmplia Therapeutics Issues New Employee Incentive Options3M ago
Company AnnouncementsAmplia Therapeutics appoints Brett Carter as director amid progress in pancreatic cancer trials3M ago
Company AnnouncementsAmplia Therapeutics reshapes board leadership as clinical momentum builds4M ago
Company AnnouncementsAmplia lodges updated ASX corporate governance statement for 20265M ago- Company AnnouncementsAmplia Therapeutics details ASX-aligned corporate governance framework5M ago
- Company AnnouncementsAmplia Highlights Cancer and Fibrosis Focus in 2025-26 Report5M ago
Company AnnouncementsAmplia Issues New Shares Under Executive Equity Plan, Affirms Regulatory Compliance5M agoCompany AnnouncementsAmplia and ANZGOG launch narmafotinib ovarian cancer trial targeting high‑need patients5M ago